Milestone-driven licensing and royalties fund a low-capex research pipeline
BioArctic combines recurring Leqembi royalties with episodic licensing, milestone, and research-collaboration receipts, making revenue and operating results uneven across periods. Capital spending is modest relative to cash generation, while research and development investment is a defining ongoing cost.